CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

A Study of BGM0504 in Participants with Type 2 Diabetes

NCT06716216 · Phase 3 · Recruiting

PHASEPhase 3

STATUSRecruiting

ENROLLMENT537

EST. COMPLETION2026-03-20

Conditions

Type 2 Diabetes Mellitus (T2DM)

Interventions

Drug: 5 mg BGM0504 Administered SCDrug:10 mg BGM0504 Administered SCDrug: Semaglutide Administered SC

Study details

SPONSORBrightGene Bio-Medical Technology Co., Ltd.

START DATE2024-11-29

Related company profiles

BrightGene Bio-Medical Technology

688166.SS

Primary source

ClinicalTrials.gov record NCT06716216 ↗

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier: NCT06716216
Event / action date: Not separately retained
Source update date: Not separately retained
Platform retrieval / processing date: Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record